Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states

Molecular Interventions

Volumn 11, Issue 2, 2011, Pages 124-132

  Kelly, Edward J ^a   Nakano, Mariko ^a   Rohatgi, Priyanka ^a   Yarov Yarovoy, Vladimir ^a   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CYTOCHROME P450; CYTOCHROME P450 4F22; CYTOCHROME P450 4V2; HEPOXILIN A; OMEGA 3 FATTY ACID; RESOLVIN; TRIOXILIN; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; DISEASE ASSOCIATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; EYE DISEASE; FATTY ACID METABOLISM; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; HYPERKERATOSIS; LAMELLAR ICHTHYOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SKIN DISEASE;

ANIMALS; CORNEAL DYSTROPHIES, HEREDITARY; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS; HUMANS; ICHTHYOSIS, LAMELLAR; RETINAL DISEASES; SUBSTRATE SPECIFICITY;

EID: 79955686815     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.11.2.10     Document Type: Review

References (59)

1. Rittle J and Green MT (2010) Cytochrome P450 compound I: Scapture,characterization, and C-H bond activation kinetics. Science 330:933-937.
2. Stark K, and Guengerich FP (2007) Characterization of orphan human cytochromes P450. Drug Metab Rev 39:627-637. (Pubitemid 47355742)
3. Hsu MH, Savas U, Griffin KJ, and Johnson EF (2007) Human cytochrome p450 family 4 enzymes: Function, genetic variation and regulation. Drug Metab Rev 39:515-538. (Pubitemid 47355735)
4. Hardwick JP (2008) Cytochrome P450 omega hydroxylase (CYP4) sfunction in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75:2263-2275.
5. Rettie AE and Kelly EJ (2008) The CYP4 family, in Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics (Ioannides C, ed), pp 385-417, Royal Society of Chemistry, Cambridge, UK.
6. Li A, Jiao X, Munier FL, Schorderet DF, Yao W, Iwata F, Hayakawa M, Kanai A, Shy Chen M, Alan Lewis R, J, et al. (2004) Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet 74:817-826. (Pubitemid 38568957)
7. Lefevre C, Bouadjar B, Ferrand V, Tadini G, Megarbane A, Lathrop M, Prud'homme JF, and Fischer J (2006) Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 15:767-776. (Pubitemid 43264701)
8. Nebert DW and Karp CL (2008) Endogenous functions of the arylhydrocarbon receptor (AHR): Intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J Biol Chem 283:36061-36065.
9. Guengerich FP, Tang Z, Cheng Q, and Salamanca-Pinzon SG (2011) Approaches to deorphanization of human and microbial cytochrome P450 enzymes. Biochim Biophys Acta 1814:139-145.
10. Bietti GB (1937) Ueber familiaeres vorkommen non 'retinitis punctata albescens' (verbunden mit 'dystrophia marginalis cristallinea corneae') glitzern des glaskoerpers und anderen degenerativen augenveraenderungen. Klin Mbl Augenheilk 99:737-757.
11. Mansour AM, Uwaydat SH, and Chan CC (2007) Long-term follow-up in Bietti crystalline dystrophy. Eur J Ophthalmol 17:680-682. (Pubitemid 351175352)
12. Zenteno JC, Ayala-Ramirez R, and Graue-Wiechers F (2008) Novel CYP4V2 gene mutation in a Mexican patient with Bietti's crystalline corneoretinal dystrophy. Curr Eye Res 33:313-318. (Pubitemid 351507756)
13. Lin J, Nishiguchi KM, Nakamura M, Dryja TP, Berson EL, and Miyake Y (2005) Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy. J Med Genet 42:e38.
14. Mataftsi A, Zografos L, Milla E, Secretan M, and Munier FL (2004) Bietti's crystalline corneoretinal dystrophy: A cross-sectional study. Retina 24:416-426. (Pubitemid 38780472)
15. Revere KE and Chung DC (2009) Recent breakthroughs in gene therapy for inherited retinal degeneration. Discov Med 8:125-129.
16. Jiao X, Munier FL, Iwata F, Hayakawa M, Kanai A, Lee J, Schorderet DF, Chen MS, Kaiser-Kupfer M, and Hejtmancik JF (2000) Genetic linkage of Bietti crystallin corneoretinal dystrophy to chromosome 4q35. Am J Hum Genet 67:1309-1313.
17. Lee KY, Koh AH, Aung T, Yong VH, Yeung K, Ang CL, and Vithana EN (2005) Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci 46:3812-3816. (Pubitemid 44264691)
18. Shan M, Dong B, Zhao X, Wang J, Li G, Yang Y, and Li Y (2005) Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy. Mol Vis 11:738-743. (Pubitemid 41410199)
19. Gekka T, Hayashi T, Takeuchi T, Goto-Omoto S, and Kitahara K (2005) CYP4V2 mutations in two Japanese patients with Bietti's crystalline dystrophy. Ophthalmic Res 37:262-269. (Pubitemid 41291539)
20. Wada Y, Itabashi T, Sato H, Kawamura M, Tada A, and Tamai M (2005) Screening for mutations in CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy. Am J Ophthalmol 139:894-899. (Pubitemid 40614777)
21. Jin ZB, Ito S, Saito Y, Inoue Y, Yanagi Y, and Nao-i N (2006) Clinical and molecular findings in three Japanese patients with crystalline retinopathy. Jpn J Ophthalmol 50:426-431. (Pubitemid 44496508)
22. Lai TY, Ng TK, Tam PO, Yam GH, Ngai JW, Chan WM, Liu DT, Lam DS, and Pang CP (2007) Genotype phenotype analysis of Bietti's crystalline dystrophy in patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci 48:5212-5220. (Pubitemid 351260934)
23. Chivian D and Baker D (2006) Homology modeling using parametric alignment ensemble generation with consensus and energy-based model selection. Nucleic Acids Res 34:e112.
24. Kim DE, Chivian D, and Baker D (2004) Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 32:W526- 531. (Pubitemid 38997389)
25. Girvan HM, Seward HE, Toogood HS, Cheesman MR, Leys D, and Munro AW (2007) Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets. New heme ligation states influence conformational equilibria in P450 BM3. J Biol Chem 282:564-572. (Pubitemid 47076604)
26. Nakano M, Kelly EJ, and Rettie AE (2009) Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug Metab Dispos 37:2119-2122.
27. Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, Rettie AE,, et al. (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:38166-38172.
28. Kaiser-Kupfer MI, Chan CC, Markello TC, Crawford MA, Caruso RC, Csaky KG, Guo J, and Gahl WA (1994) Clinical biochemical and pathologic correlations in Bietti's crystalline dystrophy. Am J Ophthalmol 118:569-582. (Pubitemid 24345618)
29. Wilson DJ, Weleber RG, Klein ML, Welch RB, and Green WR (1989) Bietti's crystalline dystrophy. A clinicopathologic correlative study. Arch Ophthalmol 107:213-221. (Pubitemid 19055340)
30. Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Gahl WA, Markello TC, Guo J, and Chader GJ (2001) The metabolism of fatty acids in human Bietti crystalline dystrophy. Invest Ophthalmol Vis Sci 42:1707-1714. (Pubitemid 32652343)
31. Lai TY, Chu KO, Chan KP, Ng TK, Yam GH, Lam DS, and Pang CP (2010) Alterations in serum fatty acid concentrations and desaturase activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes. Invest Ophthalmol Vis Sci 51:1092-1097.
32. Fliesler SJ and Anderson RE (1983) Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22:79-131.
33. Anderson RE (1970) Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. Exp Eye Res 10:339-344.
34. Giusto NM, Pasquare SJ, Salvador GA, Castagnet PI, Roque ME, and Ilincheta de Boschero MG (2000) Lipid metabolism in vertebrate retinal rod outer segments. Prog Lipid Res 39:315-391. (Pubitemid 30336471)
35. Young RW (1976) Visual cells and the concept of renewal. Invest Ophthalmol Vis Sci 15:700-725.
36. Gordon WC and Bazan NG (1993) Visualization of [3H] docosahexaenoic acid trafficking through photoreceptors and retinal pigment epithelium by electron microscopic autoradiography. Invest Ophthalmol Vis Sci 34:2402-2411. (Pubitemid 23206469)
37. Scott BL and Bazan NG (1989) Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci U S A 86:2903-2907. (Pubitemid 19112648)
38. Bazan NG (2006) Cell survival matters: Docosahexaenoic acid signaling. neuroprotection and photoreceptors. Trends Neurosci 29:263-271.
39. Ariel A and Serhan CN (2007) Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 28:176-183. (Pubitemid 46467520)
40. Dangi B, Obeng M, Nauroth JM, Teymourlouei M, Needham M, Raman K, and Arterburn LM (2009) Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J Biol Chem 284:14744-14759.
41. Christmas P, Ursino SR, Fox JW, and Soberman RJ (1999) Expression of the CYP4F3 gene: Tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omegahydroxylase. J Biol Chem 274:21191-21199.
42. Hong S, Gronert K, Devchand PR, Moussignac RL, and Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278:14677-14687. (Pubitemid 36799790)
43. Williams ML and Elias PM (1985) Heterogeneity in autosomal recessive ichthyosis. Clinical and biochemical differentiation of lamellar ichthyosis and nonbullous congenital ichthyosiform erythroderma. Arch Dermatol 121:477-488. (Pubitemid 15100839)
44. Huber M, Rettler I, Bernasconi K, Frenk E, Lavrijsen SP, Ponec M, Bon A, Lautenschlager S, Schorderet DF, and Hohl D (1995) Mutations of keratinocyte transglutaminase in lamellar ichthyosis. Science 267:525-528.
45. Bradshaw E, Leemis R, Russell PO Jr, Thomas RK, and Tabatabai, F (1995) An integrated patient information system for a primary care clinic network. Healthc Inf Manage 9:67-71.
46. Lefevre C, Audebert S, Jobard F, Bouadjar B, Lakhdar H, Boughdene- Stambouli O, Blanchet-Bardon C, Heilig R, Foglio M, Weissenbach J, et al. (2003) Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet 12:2369-2378. (Pubitemid 37160881)
47. Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, Ozguc M, Lathrop M, Prud'homme JF, and Fischer J (2002) Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 11:107-113. (Pubitemid 34100773)
48. Lefevre C, Bouadjar B, Karaduman A, Jobard F, Saker S, Ozguc M, Lathrop M, Prud'homme JF, and Fischer J (2004) Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet 13:2473-2482. (Pubitemid 39377851)
49. Lefevre C, Jobard F, Caux F, Bouadjar B, Karaduman A, Heilig R, Lakhdar H, Wollenberg A, Verret JL, Weissenbach J, et al. (2001) Mutations in CGI-58, the gene encoding a new protein of the esterase/ lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 69:1002-1012. (Pubitemid 33015815)
50. Guengerich FP, Tang Z, Salamanca-Pinzon SG, and Cheng Q (2010) Characterizing proteins of unknown function: Orphan cytochrome p450 enzymes as a paradigm. Mol Interv 10:153-163.
51. Nilsson T, Ivanov IV, and Oliw EH (2010) LC-MS/MS analysis of epoxyalcohols and epoxides of arachidonic acid and their oxygenation by recombinant CYP4F8 and CYP4F22. Arch Biochem Biophys 494:64-71.
52. Nigam S (2007) Hepoxilins: Novel enzymatic pathways and clinical significance. FEBS J 274:3493. (Pubitemid 47052413)
53. Nigam S, Zafiriou MP, Deva R, Ciccoli R, and Roux-Van der Merwe R (2007) Structure, biochemistry and biology of hepoxilins: An update. FEBS J 274:3503-3512. (Pubitemid 47052415)
54. Yu Z, Schneider C, Boeglin WE, and Brash AR (2007) Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARalpha. Lipids 42:491-497. (Pubitemid 46988480)
55. Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, and Feingold KR (2000) Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 115:353-360.56.
56. Schmuth M, Schoonjans K, Yu QC, Fluhr JW, Crumrine D, Hachem JP, Lau P, Auwerx J, Elias PM, and Feingold KR (2002) Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero. J Invest Dermatol 119:1298-1303. (Pubitemid 36005612)
57. Reynaud D, Rounova O, Demin PM, Pivnitsky KK, and Pace-Asciak CR (1997) Hepoxilin A3 is oxidized by human neutrophils into its omega-hydroxy metabolite by an activity independent of LTB4 omega- hydroxylase. Biochim Biophys Acta 1348:287-29858.
58. Rizzo WB (2007) Sjogren-Larsson syndrome: Molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab 90:1-9. (Pubitemid 44856293)
59. Ruether K, Baldwin E, Casteels M, Feher MD, Horn M, Kuranoff S, Leroy BP, Wanders RJ, and Wierzbicki AS (2010) Adult Refsum disease: A form of tapetoretinal dystrophy accessible to therapy. Surv Ophthalmol 55:531-538.